Delineating associations of progressive pleuroparenchymal fibroelastosis in patients with pulmonary fibrosis

• Published in: ERJ open research Vol. 9; no. 2; p. 637
• Main Authors: Gudmundsson, Eyjolfur, Zhao, An, Mogulkoc, Nesrin, van Beek, Frouke, Goos, Tinne, Brereton, Christopher J, Veltkamp, Marcel, Chapman, Robert, van Es, Hendrik W, Garthwaite, Helen, Gholipour, Bahareh, Heightman, Melissa, Nair, Arjun, Pontoppidan, Katarina, Savas, Recep, Ahmed, Asia, Vermant, Marie, Unat, Omer, Procter, Alex, De Sadeleer, Laurens, Denneny, Emma, Wallis, Timothy, Duncan, Mark, Taylor, Magali, Verleden, Stijn, Janes, Sam M, Alexander, Daniel C, Wells, Athol U, Porter, Joanna, Jones, Mark G, Stewart, Iain, van Moorsel, Coline H M, Wuyts, Wim, Jacob, Joseph
• Format: Journal Article
• Language: English
• Published: England European Respiratory Society 01-03-2023
• Subjects: Original s
• ISSN: 2312-0541; 2312-0541
• DOI: 10.1183/23120541.00637-2022

Computer quantification of baseline computed tomography (CT) radiological pleuroparenchymal fibroelastosis (PPFE) associates with mortality in idiopathic pulmonary fibrosis (IPF). We examined mortality associations of longitudinal change in computer-quantified PPFE-like lesions in IPF and fibrotic hypersensitivity pneumonitis (FHP).
Two CT scans 6-36 months apart were retrospectively examined in one IPF (n=414) and one FHP population (n=98). Annualised change in computerised upper-zone pleural surface area comprising radiological PPFE-like lesions (Δ-PPFE) was calculated. Δ-PPFE >1.25% defined progressive PPFE above scan noise. Mixed-effects models evaluated Δ-PPFE against change in visual CT interstitial lung disease (ILD) extent and annualised forced vital capacity (FVC) decline. Multivariable models were adjusted for age, sex, smoking history, baseline emphysema presence, antifibrotic use and diffusion capacity of the lung for carbon monoxide. Mortality analyses further adjusted for baseline presence of clinically important PPFE-like lesions and ILD change.
Δ-PPFE associated weakly with ILD and FVC change. 22-26% of IPF and FHP cohorts demonstrated progressive PPFE-like lesions which independently associated with mortality in the IPF cohort (hazard ratio 1.25, 95% CI 1.16-1.34, p<0.0001) and the FHP cohort (hazard ratio 1.16, 95% CI 1.00-1.35, p=0.045).
Progression of PPFE-like lesions independently associates with mortality in IPF and FHP but does not associate strongly with measures of fibrosis progression.